Testing effectiveness (Phase 2)Active Not RecruitingNCT01589302
What this trial is testing
PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Who this might be right for
Prolymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory/Relapsed Chronic Lymphocytic Leukemia
Kami Maddocks, MD 154